Khetsuriani N, Music S, Deforest A, Sutter R W
Tbilisi Office of the US Centers for Disease Control and Prevention, Tbilisi, Georgia and National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
J Infect Dis. 2000 Feb;181 Suppl 1:S208-12. doi: 10.1086/315559.
To determine the immunogenicity and safety of a single dose of diphtheria toxoid among adults, blood samples for detecting serum antitoxin levels were obtained from 18- to 59-year-old subjects (n=248) before and 30 days after immunization with Td (tetanus-diphtheria toxoids; manufactured by Serum Institute of India). By day 30, the seroprevalence of antitoxin levels >/=0.1 IU/mL increased from 22.6% to 81.5%; median antitoxin levels increased from 0.01 to 4.0 IU/mL. These parameters were lowest among subjects who were 40-59 years old, especially among those 40-49 years old. Adverse reactions (local redness, swelling, induration, fever>39 degrees C) were reported by 5.3% of participants. Our findings suggest that, in general, one dose of the Indian-produced Td vaccine is efficacious and safe in inducing an adequate immune response against diphtheria in adults; however, in Georgia, persons 40-59 years old, especially those 40-49 years old, will require additional doses of toxoid to achieve protective levels of antitoxin.
为确定一剂白喉类毒素在成人中的免疫原性和安全性,在18至59岁受试者(n = 248)接种Td(破伤风-白喉类毒素;由印度血清研究所生产)前及接种后30天采集血样检测血清抗毒素水平。至第30天,抗毒素水平≥0.1 IU/mL的血清阳性率从22.6%增至81.5%;抗毒素水平中位数从0.01 IU/mL增至4.0 IU/mL。这些参数在40至59岁受试者中最低,尤其是40至49岁者。5.3%的参与者报告有不良反应(局部发红、肿胀、硬结、发热>39摄氏度)。我们的研究结果表明,总体而言,一剂印度生产的Td疫苗在诱导成人对白喉产生充分免疫应答方面有效且安全;然而,在格鲁吉亚,40至59岁的人,尤其是40至49岁者,需要额外接种类毒素以达到抗毒素的保护水平。